Sign In
Buy SLRX
$0.84
+0 (+0%)
At Close: Apr 14, 2026
Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference
07:33am, Friday, 09'th Jul 2021
HOUSTON, July 09, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric canc
REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
08:03am, Thursday, 17'th Jun 2021
Online Event Scheduled for Monday, June 21, 2021, at 2:00 p.m., ET
Salarius Pharmaceuticals Launches Mid-Stage Blood Cancer Trial With Seclidemstat
11:45am, Tuesday, 15'th Jun 2021
Salarius Pharmaceuticals Inc (NASDAQ: SLRX) has initiated an investigator-initiated Phase 1/2 trial to investigate seclidemstat as a potential treatment for hematologic cancers. The trial will be a
Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers
07:30am, Tuesday, 15'th Jun 2021
Clinical trial to target patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), both cancers that can progress into Acute Myeloid Leukemia (AML) Clinical trial to ta
Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
01:30pm, Thursday, 10'th Jun 2021
Online Event Scheduled for Monday, June 21, 2021 at 2:00 p.m., ET
Presentations highlight full data from dose-escalation stage of Phase 1/2 clinical trial in Ewing sarcoma and interim data from Advanced Solid Tumor (AST) trial
Preliminary drug activity observed in both relapsed/refractory Ewing sarcoma and Advanced Solid Tumor (AST) trials
Penny Stocks On Robinhood For You May 2021 Watch List
04:31pm, Sunday, 16'th May 2021
Robinhood penny stocks to watch for the next half of May The post Penny Stocks On Robinhood For You May 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2021 Results - Earnings Call Transcript
07:52pm, Wednesday, 12'th May 2021
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2021 Results - Earnings Call Transcript
Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights
04:05pm, Wednesday, 12'th May 2021
Cash and Cash Equivalents of $36.6M, More Than Sufficient to Fund Completion of the Current Clinical Trials of Lead Drug Candidate, Seclidemstat
Salarius Pharmaceuticals to Report First Quarter 2021 Financial Results
07:05am, Wednesday, 05'th May 2021
Conference Call and Live Audio Webcast Scheduled for Wednesday, May 12, 2021, 5:00 p.m. ET Conference Call and Live Audio Webcast Scheduled for Wednesday, May 12, 2021, 5:00 p.m. ET
HOUSTON, April 19, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric can
Salarius: Early Stage Nano Cap Targeting Cancer
05:44pm, Monday, 05'th Apr 2021
SLRX is a low market cap early-stage cancer therapeutics company. It has a very low cash reserve.
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q4 2020 Results - Earnings Call Transcript
06:42pm, Thursday, 18'th Mar 2021
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q4 2020 Results - Earnings Call Transcript
Recap: Salarius Pharmaceuticals Q4 Earnings
05:26pm, Thursday, 18'th Mar 2021
Shares of Salarius Pharmaceuticals (NASDAQ:SLRX) higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 77.27% over the past year to ($0.1
